SP-0338: Neuro-cognitive sequelae after brain irradiation  by Kortmann, R.D.
S166                                                                                                                                         3rd ESTRO Forum 2015 
 
planning. After 3 months a complete response was observed 
in 46%, and 7% had partial response.  
Conclusions: Using the HYPERcollar, deep hyperthermia 
treatment of HNC was found to be safe, feasible, with good 
compliance and promising outcome. These promising early 
clinical results culminated in the use of hyperthermia as a 
standard addition to reirradiation. We will now embark on a 
study for (chemo-)irradiation combined with hyperthermia in 
primary head and neck cancer.  
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Randomized controlled trials (RCTs) are the gold standard for 
comparative effectiveness research of medical interventions. 
Treatment guidelines rank evidence of using a hierarchy with 
evidence from RCTs at the highest level, Level I. Many 
authorities require Level I evidence from RCTs for 
registration and reimbursement of a new drug. When Level I 
evidence is not available, the treatment is often viewed as 
being “unproven”. Ideally, every new diagnostic or 
interventional procedure should be tested in RCTs before 
becoming standard care to avoid ineffective or harmful 
treatments. The reason is that even treatments supported by 
a clear biological rationale and strong pre-clinical data may 
not produce a therapeutic gain; examples include the 
detrimental effect of erythropoietin when used together with 
radiotherapy for head and neck cancer  or class 1c 
antiarrhythmic agents in myocardial infarction patients . The 
unexpected result of these studies provides a strong 
argument in favour of randomization.   
Engineers and physicists often tackle the problem of 
obtaining “evidence” by making models to calculate the 
quantitative relationship between parameters and a 
particular outcome. The acceptance of the latter kind of 
empirical model spring from its ability to predict the 
outcome of experiments with accuracy, reliability and 
prospective reproducibility that is sufficient to be useful. The 
analogy with human biology is far from perfect because of 
the complexity of the processes involved. In physics 
controlling a rather limited set of known experimental 
conditions will suffice to standardize outcome 
measurements. The utility of models predicting clinically 
relevant outcomes could theoretically indeed be established 
by prospective comparisons between expected and observed 
outcomes. However, this is no simple task and has not been 
accomplished convincingly in the past. Nearly all proton 
therapy studies are retrospective, with heterogeneous 
patient groups recruited over long time periods, treated with 
varying techniques and with often very incomplete follow-up 
data. The radiobiology of the complex DNA damage in the 
Bragg peak is large unexplored and is not taken into account 
in current proton TPS. Some TCP and NTCP models are 
without doubt of merit for photon therapy, but they should 
not be extrapolated blindly to proton therapy as long as the 
latter models too have undergone extensive validation. The 
model-based approach is clearly a field where much more 
research is needed before this can be accepted as an 
alternative for RCTs. Except for some quite extreme cases, 
e.g. in some CNS and childhood tumours, randomised trials 
are still necessary, scientifically, legally and for obtaining 
reimbursement.   
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Purpose / Objective: Cognitive impairment is frequently 
present in childhood brain tumour survivors and greatly 
impacts psychosocial development and quality of survival. 
Major contributing factors are related to tumour, the 
presence of hydrocephalus, surgery, chemotherapy and 
radiotherapy. The neurocognitive functions primarily involved 
are including memory, attention, visual perceptual ability 
and verbal function.  
Materials and Methods: The majority of data are essentially 
based on past treatments with varying treatment volumes 
(craniospinal irradiation followed by a boost, whole brain 
irradiation, local irradiation with varying dose prescriptions) 
for medulloblastoma, low grade glioma, ependymoma, germ 
cell tumours and leukemia. The literature is replete of data 
based on retrospective evaluations spanning many years 
during which general disease management was improved. 
Additionally, radiotherapeutic approaches considerably 
changed with the introduction of 3 D conformal technologies 
including IMRT and recently proton therapy that essentially 
permit a more precise coverage of tumour while sparing 
normal brain tissue.  
Results: Post radiation changes include a wide spectrum of 
abnormalities from subclinical changes detectable only by 
MRI to focal neurological deficits and intellectual 
impairment. It appears that all changes are likely to result 
from complex alterations within several functional 
compartments with the following contributing factors: 
damage to vessel structures, deletion of oligodendrocyte 
progenitor cells and mature oligodendrocytes (white matter), 
deletion of neural stem cell population in the hippocampus. 
Additionally, the tumours significantly differ between the 
inherent disabling potential with respect to tumour location 
and the therapeutic approach. The major risk factors are 
young age at treatment and a dose relationship in whole 
brain irradiation. Recent data indicate that particular 
radiosensitive regions of the brain are more susceptible to 
the adverse effects of radiation such as frontal lobes, 
temporal lobe and hippocampus including anatomical 
subcompartments in which neurogenesis occurs 
(subventricular zone). However, the relationship between 
radiation dose to these areas and a decline in neurocognitive 
function remains a controversial issue. Recent data indicate 
that radiation dose to neuronal progenitor cell niches and 
temporal lobes causes a decline in cognitive function. Modern 
radiotherapy technologies are able to selectively reduce the 
dose to organs at risk. Correspondingly, reducing the dose to 
the hippocampus in adults appears to preserve memory with 
conformal avoidance of the hippocampal neural stem cell 
compartment during whole-brain radiotherapy (recently 
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published RTOG study 0933). Assessment of health status and 
neurocognitive function after hyperfractionated radiotherapy 
of CSA in the SIOP PNET IV trial showed in part a better 
outcome as compared with conventional fractionation, 
especially in younger children. 
Conclusions: The impact of radiotherapy on the risk for late 
effects and its clinical pattern apparently strongly depends 
on the exposure of functionally relevant regions within the 
brain to irradiation. Neuroregeneration and the preservation 
of the corresponding anatomical regions may play an 
important role in the reduction of radiation induced decline 
of cognitive function. The impact of fractionation on the risk 
to develop a decline in neurocognitive function is 
controversial and requires further research.            
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Purpose: Reported experiences focusing on vulvo-vaginal 
brachytherapy during childhood are rare and most reported 
children have been treated at Gustave Roussy in France. Our 
technique of gynaecological brachytherapy has always 
been anatomy-adapted with use of the mould applicator. 
Here, we assessed the long-term toxicities of conservative 
treatments integrating brachytherapy in female survivors 
with localized vulvo-vaginal tumors. 
Patients and Methods: The data from 42 patients treated at 
Gustave Roussy between 1971 and 2004, were both 
retrospectively and prospectively analyzed. Strictly 
confidential surveys buildup based on the LENT SOMA 
questionnaires were mailed and 51% were filled up (minor: 
29%; adult: 71%). Complications were recorded throughout 
follow-up and graded according to the CTCAE version 4.0. 
Results: The median age at diagnosis was 1.7 years (range, 
0.6-16.6) and most patients (69%) had rhabdomyosarcomas. 
Treatments included brachytherapy for all patients, 
chemotherapy (88%), surgery (31%), and external-beam 
radiotherapy (5%). At a median follow-up of 15.5 years, 
41/42 patients were alive. There was 160 late effects 
identified in 32/42 (76%) patients: 72% G1-G2, and 28% G3-4 
(mean all grade late effect per patients: 4±4 [median: 2.5; 
range, 0-16] and mean G3-4 late effect per patients: 1±1.9 
[median: 0; range, 0-8]). The most commons late toxicities 
were gynecologic for all grade (75/160; 47%) and urinary for 
G3-4 (24/45; 53%). Fourteen patients (33%) required surgical 
treatment of late complications. The 15-year actuarial 
incidence rate of G3-4 late effects was 51%. The total 
number of all grade and G3-4 late effects was significantly 
increased in patients treated before 1990 (p=0.005 and 
p=0.008) and with higher cumulated dose (p=0.03 and 
p=0.02) and maximal dose delivered to ovaries (p=0.002 and 
p=0.04), and larger brachytherapy volume (p=0.03 and 
p=0.02). Quality of life was good or very good in 91% of 
patients that answered the surveys.  
Conclusion: The burden of late effects decreased with 
advances in treatment. A highly specialized multidisciplinary 
approach combining stringently controlled brachytherapy 
parameters, elective surgical indications, and efficient 
chemotherapy regimens should allow pursue improvements in 
terms of long-term sequelae. 
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Side effects after external radiotherapy in pediatric oncology 
are multifaceted and depend on the age of the patient at 
time of treatment, location, size of the target volume, and 
the OAR inside or in the neighborhood of the target. Not only 
high doses do have an effect on the growing structures but as 
well low doses can provoke severe long term side effects. 
Most of the side effects are not visible during the first 5 years 
after treatment but develop continuously over decades, and 
can influence quality of lifelong. Based on the experience in 
pediatric radiooncology and dose distribution at the growing 
structures, most of these side effects are predictable and 
some of them are avoidable using adequate techniques. 
According to the age of the patient different long term side 
effects are to be aspected. For example children in the of > 
than 9 years after mantel field irradiation have a much 
higher risk to develop breast carcinoma than younger 
children, meanwhile the growing deficit of the bones are 
much pronounced after RT in younger children than in older 
ones. Due to the combined treatment schedules most of the 
side effects are combined and the real dimension of RT–dose 
and irradiated volume cannot always be evaluated. Based on 
different patient cases the development of long term side 
effects will be discussed. 
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Purpose/Objective: Improved childhood cancer survival is 
accompanied by an increased incidence of tumor- and 
treatment-related adverse events later in life. 
Cerebrovascular accidents (CVAs) including ischemic and 
hemorrhagic stroke are amongst the most serious events. The 
purpose of this study was to determine the incidence and 
severity of symptomatic CVAs occurring 5 years or later after 
the primary cancer diagnosis in a cohort of long-term 
childhood cancer survivors, and to assess dose-effect 
relationships for cranial radiotherapy (CRT) and 
supradiaphragmatic radiotherapy (SDRT). 
Materials and Methods: The single-center study cohort 
consisted of 1362 ≥5-year survivors diagnosed between 1966 
and 1996; two survivors who had a CVA within 5 years after 
diagnosis were excluded from the cohort. CVAs were 
clinically confirmed, and defined and graded for severity 
using the Common Terminology Criteria for Adverse Events 
(CTCAEv.3.0). Physical radiation doses were available for 411 
(93.8%) of the 438 survivors treated with CRT and/or SDRT, 
and converted into the equivalent dose in 2-Gy fractions 
(EQD2). Cox proportional hazard models were used to 
estimate the hazard ratio (HR) and 95% confidence interval 
(95%CI) for sex, age at diagnosis, brain surgery, 
chemotherapy, CRT and SDRT. In a second model, the 
